Loading
Add immunotherapy to the two targeted pills in the most aggressive thyroid cancer, because the combination has produced multi-year survivors in early series.
The idea is to make dabrafenib and trametinib plus pembrolizumab the standard first-line treatment for BRAF V600E-mutant anaplastic thyroid cancer. Anaplastic thyroid cancer is immunologically hot relative to differentiated cancers, with high PD-L1 expression and mutational burden, and targeted therapy induces rapid antigen release that checkpoint blockade can exploit. MD Anderson series of the triplet report multi-year survivors and longer overall survival than the doublet, building on the anaplastic cohort of the ROAR trial. The hypothesis is that adding pembrolizumab extends overall survival; given the rarity of the disease, the test is an international randomised phase 2 of doublet versus triplet with survival at one year as primary endpoint.
One of the most cited trial reports Europe PMC returns for BRAF in Thyroid cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for BRAF in Thyroid cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for BRAF in Thyroid cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares ROAR (anaplastic thyroid cancer cohort), Dabrafenib + trametinib, BRAF, Thyroid cancer.
Shares ROAR (anaplastic thyroid cancer cohort), BRAF, Thyroid cancer.
Shares Thyroid cancer, PD-1, Pembrolizumab.
Shares Dabrafenib + trametinib, BRAF.
Shares Dabrafenib + trametinib, BRAF, PD-1.
Shares BRAF, PD-1, Pembrolizumab.
Shares Dabrafenib + trametinib, BRAF.